Related Experiment Video

Updated: May 23, 2026

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Biologic agents for immune checkpoint inhibitor-associated cutaneous adverse events: a retrospective cohort study at

Duc V Le1, Hue T T Tran1, Raslina Shrestha2

  • 1Department of Dermatology, Mayo Clinic, Rochester, MN, USA; National Hospital of Dermatology and Venereology, Hanoi, Vietnam.

Journal of the American Academy of Dermatology
|May 21, 2026
PubMed
Abstract

No abstract available in PubMed .

Keywords:
biologic therapycutaneous immune-related adverse eventsdermatologic toxicityimmune checkpoint inhibitorsretrospective study

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.